Management and outcomes following pancreaticoduodenectomy for ampullary adenocarcinoma

M. T. Chavez, J. P. Sharpe, T. O'Brien, K. T. Patton, D. C. Portnoy, Noam Vanderwalde, Jeremiah Deneve, David Shibata, S. W. Behrman, P. V. Dickson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Introduction: The purpose of this study was to evaluate outcomes following pancreaticoduodenectomy(PD) for ampullary adenocarcinoma(AAC). Methods: We evaluated patients having undergone PD for AAC and the impact of clinical/histopathologic factors and adjuvant therapy(AT) on survival. Results: 52 patients underwent potentially curative PD. Perineural and lymphovascular invasion were associated with decreased survival. There was no difference in survival between patients treated with PD vs. PD+AT, however, AT was more often administered to patients with N1 vs. N0 and stage II/III vs. I disease. Among patients receiving AT, we observed a trend towards improved survival when radiation was included. Recurrence occurred in 7/18(39%) stage I patients, only 2(7%) of which received AT. Conclusion: AT did not improve survival, however was more commonly administered in advanced disease. Stage I patients had high recurrence rates but rarely received AT. Prospective evaluation of appropriate AT regimens and use in early stage patients should be considered.

Original languageEnglish (US)
Pages (from-to)856-861
Number of pages6
JournalAmerican Journal of Surgery
Volume214
Issue number5
DOIs
StatePublished - Nov 1 2017

Fingerprint

Pancreaticoduodenectomy
Adenocarcinoma
Survival
Therapeutics
Recurrence
Radiation

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Chavez, M. T., Sharpe, J. P., O'Brien, T., Patton, K. T., Portnoy, D. C., Vanderwalde, N., ... Dickson, P. V. (2017). Management and outcomes following pancreaticoduodenectomy for ampullary adenocarcinoma. American Journal of Surgery, 214(5), 856-861. https://doi.org/10.1016/j.amjsurg.2017.01.029

Management and outcomes following pancreaticoduodenectomy for ampullary adenocarcinoma. / Chavez, M. T.; Sharpe, J. P.; O'Brien, T.; Patton, K. T.; Portnoy, D. C.; Vanderwalde, Noam; Deneve, Jeremiah; Shibata, David; Behrman, S. W.; Dickson, P. V.

In: American Journal of Surgery, Vol. 214, No. 5, 01.11.2017, p. 856-861.

Research output: Contribution to journalArticle

Chavez, M. T. ; Sharpe, J. P. ; O'Brien, T. ; Patton, K. T. ; Portnoy, D. C. ; Vanderwalde, Noam ; Deneve, Jeremiah ; Shibata, David ; Behrman, S. W. ; Dickson, P. V. / Management and outcomes following pancreaticoduodenectomy for ampullary adenocarcinoma. In: American Journal of Surgery. 2017 ; Vol. 214, No. 5. pp. 856-861.
@article{42bf322fc87148f19cc7dacd000fb649,
title = "Management and outcomes following pancreaticoduodenectomy for ampullary adenocarcinoma",
abstract = "Introduction: The purpose of this study was to evaluate outcomes following pancreaticoduodenectomy(PD) for ampullary adenocarcinoma(AAC). Methods: We evaluated patients having undergone PD for AAC and the impact of clinical/histopathologic factors and adjuvant therapy(AT) on survival. Results: 52 patients underwent potentially curative PD. Perineural and lymphovascular invasion were associated with decreased survival. There was no difference in survival between patients treated with PD vs. PD+AT, however, AT was more often administered to patients with N1 vs. N0 and stage II/III vs. I disease. Among patients receiving AT, we observed a trend towards improved survival when radiation was included. Recurrence occurred in 7/18(39{\%}) stage I patients, only 2(7{\%}) of which received AT. Conclusion: AT did not improve survival, however was more commonly administered in advanced disease. Stage I patients had high recurrence rates but rarely received AT. Prospective evaluation of appropriate AT regimens and use in early stage patients should be considered.",
author = "Chavez, {M. T.} and Sharpe, {J. P.} and T. O'Brien and Patton, {K. T.} and Portnoy, {D. C.} and Noam Vanderwalde and Jeremiah Deneve and David Shibata and Behrman, {S. W.} and Dickson, {P. V.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.amjsurg.2017.01.029",
language = "English (US)",
volume = "214",
pages = "856--861",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Management and outcomes following pancreaticoduodenectomy for ampullary adenocarcinoma

AU - Chavez, M. T.

AU - Sharpe, J. P.

AU - O'Brien, T.

AU - Patton, K. T.

AU - Portnoy, D. C.

AU - Vanderwalde, Noam

AU - Deneve, Jeremiah

AU - Shibata, David

AU - Behrman, S. W.

AU - Dickson, P. V.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Introduction: The purpose of this study was to evaluate outcomes following pancreaticoduodenectomy(PD) for ampullary adenocarcinoma(AAC). Methods: We evaluated patients having undergone PD for AAC and the impact of clinical/histopathologic factors and adjuvant therapy(AT) on survival. Results: 52 patients underwent potentially curative PD. Perineural and lymphovascular invasion were associated with decreased survival. There was no difference in survival between patients treated with PD vs. PD+AT, however, AT was more often administered to patients with N1 vs. N0 and stage II/III vs. I disease. Among patients receiving AT, we observed a trend towards improved survival when radiation was included. Recurrence occurred in 7/18(39%) stage I patients, only 2(7%) of which received AT. Conclusion: AT did not improve survival, however was more commonly administered in advanced disease. Stage I patients had high recurrence rates but rarely received AT. Prospective evaluation of appropriate AT regimens and use in early stage patients should be considered.

AB - Introduction: The purpose of this study was to evaluate outcomes following pancreaticoduodenectomy(PD) for ampullary adenocarcinoma(AAC). Methods: We evaluated patients having undergone PD for AAC and the impact of clinical/histopathologic factors and adjuvant therapy(AT) on survival. Results: 52 patients underwent potentially curative PD. Perineural and lymphovascular invasion were associated with decreased survival. There was no difference in survival between patients treated with PD vs. PD+AT, however, AT was more often administered to patients with N1 vs. N0 and stage II/III vs. I disease. Among patients receiving AT, we observed a trend towards improved survival when radiation was included. Recurrence occurred in 7/18(39%) stage I patients, only 2(7%) of which received AT. Conclusion: AT did not improve survival, however was more commonly administered in advanced disease. Stage I patients had high recurrence rates but rarely received AT. Prospective evaluation of appropriate AT regimens and use in early stage patients should be considered.

UR - http://www.scopus.com/inward/record.url?scp=85014759343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014759343&partnerID=8YFLogxK

U2 - 10.1016/j.amjsurg.2017.01.029

DO - 10.1016/j.amjsurg.2017.01.029

M3 - Article

VL - 214

SP - 856

EP - 861

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 5

ER -